APGE vs REGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. APGE and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined APGE and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Apogee Therapeutics was founded in 2022 and went public in July 2023, and it runs on a single engineering premise: take inflammation and immunology targets that are already clinically validated, then re-build the antibody so it stays in the body far longer. The point is dosing interval. Existing biologics for atopic dermatitis are typically injected every two weeks, and Apogee's half-life-extended molecules are designed for quarterly or even less frequent maintenance dosing. The lead program is zumilokibart (APG777), an anti-IL-13 monoclonal antibody. Its Phase 2 APEX trial in atopic dermatitis read out positive 52-week Part A data in March 2026 and then positive 16-week Part B induction data on May 27, 2026, where about 65.9% of mid-dose patients reached EASI-75 against roughly 23.4% on placebo, with all primary and secondary endpoints met. Behind it sit APG990 (anti-OX40L), the APG279 combination of APG777 plus APG990 in Phase 1 with proof-of-concept data guided for the second half of 2026, APG808 (anti-IL-4Ra) in Phase 1b for asthma, and preclinical APG333 (anti-TSLP). The company has roughly 261 employees in Waltham, Massachusetts, and no product revenue.

Full APGE guide

Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base.

Full REGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• APGE drivers: The AbbVie cash price is now the ceiling; The shareholder vote and regulatory clearance are the remaining gates.
• REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is binary and no longer scientific: if the merger fails to close, the reference point is the pre-announcement price near $90, roughly a third below where shares trade today, and possibly lower given how much event-driven capital has rotated in. For REGN, the clearest risk is Eylea biosimilar erosion.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick APGE if you believe its drivers more; REGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the APGE and REGN guides.

APGE. Conventional valuation multiples do not apply here twice over: Apogee has no revenue and no earnings to anchor a multiple, and the price is contractually pinned to a cash offer rather than set by fundamentals. The relevant number is the spread, roughly 0.5% between the $134.49 quote and the $135.11 price, which is the market's implied compensation for the risk that the August 11 vote or regulatory clearance does not go as expected. For reference, shares changed hands at $70 in the March 2026 equity offering and near $90 just before the deal was announced, so the balance sheet and pipeline supported far less than the current quote.

REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron reported about 19% revenue growth and adjusted EPS of roughly $9.47 in Q1 2026, beating estimates, and authorized an additional $3 billion buyback. The mid-teens P/E reflects the market weighing strong Dupixent growth against expected Eylea biosimilar erosion.

Headline figures (approximate, August 2026): APGE shows cash, equivalents and marketable securities ~$1.3 billion at March 31, 2026, versus ~$902.9 million at year-end 2025, cash runway Guided into 2029, before drawing the Blackstone facility of up to ~$1.3 billion, r&d expense (q1 2026) ~$60.8 million, the bulk of operating spend, net loss ~$74.1 million in Q1 2026 (versus ~$55.3 million a year earlier), ~$274 million trailing twelve months; REGN shows total revenue (ttm, approx) ~$14 billion, q1 2026 total revenue ~$3.6 billion (up ~19% YoY), dupixent global net sales (q1 2026) ~$4.9 billion (up ~31%), eylea + eylea hd u.s. net sales (q1 2026) ~$941 million combined.

APGE and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined APGE and REGN exposure against your real portfolio. It is not an investment adviser.